Differentially expressed renal cell carcinoma

In recent RT-PCR studies, many kallikreins have been proposed as new biomarkers for malignancies other than prostate cancer. Breast, ovarian, and testicular cancers are the most studied. Certain kallikreins were found to be differentially expressed in various malignancies (up- or downregulated), and the increase or decrease of their expression may be associated with prognosis [43, 58, 70, 89-94]. We have immunohistochemically evaluated some kallikreins in malignant diseases, including two series of prostate and renal cell carcinoma, and have examined their prognostic values [84, 85]. 

Gaffey MJ, Traweek ST, Mills SE, et al. Cytokeratin expression in adrenocortical neoplasia An immunohistochemical and biochemical study with implications for the differential diagnosis of adrenocortical, hepatocellular and renal cell carcinoma. Hum Pathol. 1992 23 144-153. 

Bahrami S, Malone JC, Lear S, Martin AW. CDIO expression in cutaneous adnexal neoplasms and a potential role for differentiating cutaneous metastatic renal cell carcinoma. Arch Pathol Lab Med. 2006 130 1315-1319. 

Grignon DJ, Abdel-Malak M, Mertens WC, et al. Glutathione S-transferase expression in renal cell carcinoma a new marker of differentiation. Mod Pathol. 1994 7 186. 

Leroy X, Zini L, Leteurtre E, et al. Morphologic subtyping of papillary renal cell carcinoma correlation with prognosis and differential expression of MUCl between the two subtypes. Mod Pathol. 2002 15 1126. 

Baba, M., Nakaigawa, N., Ishiguro, H., Hamada, K., Inayama, Y, Kishida, T., Hattori, K., etaJ. (2005). Gene expression analysis of renal carcinoma adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J. Pathol. 205, 377-387. 

---